Cariprazine Augmentation in Treatment-Resistant Bipolar Depression: Data from a Retrospective Observational Study
CONCLUSION: Cariprazine seems to be an effective and well tolerated option in the management of patients with treatment resistant bipolar depression.PMID:38288838 | DOI:10.2174/1570159X22666240129095852 (Source: Current Neuropharmacology)
Source: Current Neuropharmacology - January 30, 2024 Category: Drugs & Pharmacology Authors: Elena Teobaldi Enrico Pessina Azzurra Martini Carlo Ignazio Cattaneo Domenico De Berardis Vassilis Martiadis Giuseppe Maina Gianluca Rosso Source Type: research
Thematic Selection: Stress and Stress-related Disorders Neurobiology & amp; Translational Aspects of Stress-related Disorders (Part 3)
Curr Neuropharmacol. 2024;22(5):808-809. doi: 10.2174/1570159X2205231107115145.NO ABSTRACTPMID:38284336 | PMC:PMC10845089 | DOI:10.2174/1570159X2205231107115145 (Source: Current Neuropharmacology)
Source: Current Neuropharmacology - January 29, 2024 Category: Drugs & Pharmacology Authors: Agorastos Agorastos Source Type: research
Thematic Selection: Stress and Stress-related Disorders Posttraumatic Stress Disorder (Part 2)
Curr Neuropharmacol. 2024;22(4):522-523. doi: 10.2174/1570159X2204231106143917.NO ABSTRACTPMID:38284340 | PMC:PMC10845103 | DOI:10.2174/1570159X2204231106143917 (Source: Current Neuropharmacology)
Source: Current Neuropharmacology - January 29, 2024 Category: Drugs & Pharmacology Authors: Agorastos Agorastos Source Type: research
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Curr Neuropharmacol. 2024;22(4):636-735. doi: 10.2174/1570159X22666231027111147.ABSTRACTPost-traumatic stress disorder (PTSD) is a mental health condition that can occur following exposure to a traumatic experience. An estimated 12 million U.S. adults are presently affected by this disorder. Current treatments include psychological therapies (e.g., exposure-based interventions) and pharmacological treatments (e.g., selective serotonin reuptake inhibitors (SSRIs)). However, a significant proportion of patients receiving standard-of-care therapies for PTSD remain symptomatic, and new approaches for this and other trauma-rela...
Source: Current Neuropharmacology - January 29, 2024 Category: Drugs & Pharmacology Authors: Tamar Glatman Zaretsky Kathleen M Jagodnik Robert Barsic Josimar Hernandez Antonio Philip A Bonanno Carolyn MacLeod Charlotte Pierce Hunter Carney Morgan T Morrison Charles Saylor George Danias Lauren Lepow Rachel Yehuda Source Type: research
Affective and Cognitive Impairments in Rodent Models of Diabetes
Curr Neuropharmacol. 2024 Jan 24. doi: 10.2174/1570159X22666240124164804. Online ahead of print.ABSTRACTDiabetes and related acute and long-term complications have a profound impact on cognitive, emotional, and social behavior, suggesting that the central nervous system (CNS) is a crucial substrate for diabetic complications. When anxiety, depression, and cognitive deficits occur in diabetic patients, the symptoms and complications related to the disease worsen, contributing to lower quality of life while increasing health care costs and mortality. Experimental models of diabetes in rodents are a fundamental and valuable t...
Source: Current Neuropharmacology - January 27, 2024 Category: Drugs & Pharmacology Authors: Enza Palazzo Ida Marabese Serena Boccella Carmela Belardo Gorizio Pierretti Sabatino Maione Source Type: research
Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?
Curr Neuropharmacol. 2024 Jan 24. doi: 10.2174/1570159X22666240124114126. Online ahead of print.ABSTRACTMultiple sclerosis (MS) is the most prevalent chronic autoimmune inflammatory- demyelinating disorder of the central nervous system (CNS). It usually begins in young adulthood, mainly between the second and fourth decades of life. Usually, the clinical course is characterized by the involvement of multiple CNS functional systems and by different, often overlapping phenotypes. In the last decades, remarkable results have been achieved in the treatment of MS, particularly in the relapsing- remitting (RRMS) form, thus impro...
Source: Current Neuropharmacology - January 26, 2024 Category: Drugs & Pharmacology Authors: Carlo Maria Bellanca Egle Augello Alice Mariottini Gabriele Bonaventura Valentina La Cognata Giulia Di Benedetto Anna Flavia Cantone Giuseppe Attaguile Rosaria Di Mauro Giuseppina Cantarella Luca Massacesi Renato Bernardini Source Type: research
Thematic Selection: Stress and Stress-related Disorders Developmental and Neuroendocrine Aspects of Stress and Stress-related Disorders (Part 1)
Curr Neuropharmacol. 2024;22(3):348-349. doi: 10.2174/1570159X2203231024142551.NO ABSTRACTPMID:38214276 | PMC:PMC10845080 | DOI:10.2174/1570159X2203231024142551 (Source: Current Neuropharmacology)
Source: Current Neuropharmacology - January 12, 2024 Category: Drugs & Pharmacology Authors: Agorastos Agorastos Source Type: research
In Vitro Blood-Brain Barrier Models for Neuroinfectious Diseases: A Narrative Review
Curr Neuropharmacol. 2023 Dec 8. doi: 10.2174/1570159X22666231207114346. Online ahead of print.ABSTRACTThe blood-brain barrier (BBB) is a complex, dynamic, and adaptable barrier between the peripheral blood system and the central nervous system. While this barrier protects the brain and spinal cord from inflammation and infection, it prevents most drugs from reaching the brain tissue. With the expanding interest in the pathophysiology of BBB, the development of in vitro BBB models has dramatically evolved. However, due to the lack of a standard model, a range of experimental protocols, BBB-phenotype markers, and permeabili...
Source: Current Neuropharmacology - December 11, 2023 Category: Drugs & Pharmacology Authors: Ahmad Hussein Badawi Nur Afiqah Mohamad Johnson Stanslas Brian P Kirby Vasantha Kumari Neela Rajesh Ramasamy Hamidon Basri Source Type: research
Redox Modulation of Meniere Disease by Coriolus Versicolor Treatment, a Nutritional Mushroom Approach with Neuroprotective Potential
CONCLUSIONS: Our study suggests MD as a model of cochlear neurodegenerative disease for the identification of potent inducers of the Nrf2-vitagene pathway, able to reduce the deleterious consequences associated with neurodegenerative damage, probably by indirectly acting on α-synuclein expression and on inflammatory processes NF- kB-mediated.PMID:38073105 | DOI:10.2174/1570159X22666231206153936 (Source: Current Neuropharmacology)
Source: Current Neuropharmacology - December 11, 2023 Category: Drugs & Pharmacology Authors: Rosanna Di Paola Rosalba Siracusa Roberta Fusco Marialaura Ontario Gaetano Cammilleri Licia Pantano Maria Scuto Mario Tomasello Sestina Span ò Angela Trovato Salinaro Ali S Abdelhameed Vincenzo Ferrantelli Antonio Arcidiacono Tilman Fritsch Gabriella Lup Source Type: research
Biphasic Hormetic-like Effect of Lebecetin, a C-type Lectin of Snake Venom, on Formalin-induced Inflammation in Mice
CONCLUSION: These findings implicate specific roles of integrins in inflammation and tonic pain, as well as in the related central nervous system sequelae.PMID:38073106 | DOI:10.2174/1570159X22999231207105743 (Source: Current Neuropharmacology)
Source: Current Neuropharmacology - December 11, 2023 Category: Drugs & Pharmacology Authors: Carmela Belardo Jed Jebali Serena Boccella Rosmara Infantino Antimo Fusco Michela Perrone Roozbe Bonsale Iolanda Manzo Monica Iannotta Damiana Scuteri Franca Ferraraccio Iacopo Panares Giovanna Ferrara Francesca Guida Livio Luongo Enza Palazzo Najet Srair Source Type: research
In Vitro Blood-Brain Barrier Models for Neuroinfectious Diseases: A Narrative Review
Curr Neuropharmacol. 2023 Dec 8. doi: 10.2174/1570159X22666231207114346. Online ahead of print.ABSTRACTThe blood-brain barrier (BBB) is a complex, dynamic, and adaptable barrier between the peripheral blood system and the central nervous system. While this barrier protects the brain and spinal cord from inflammation and infection, it prevents most drugs from reaching the brain tissue. With the expanding interest in the pathophysiology of BBB, the development of in vitro BBB models has dramatically evolved. However, due to the lack of a standard model, a range of experimental protocols, BBB-phenotype markers, and permeabili...
Source: Current Neuropharmacology - December 11, 2023 Category: Drugs & Pharmacology Authors: Ahmad Hussein Badawi Nur Afiqah Mohamad Johnson Stanslas Brian P Kirby Vasantha Kumari Neela Rajesh Ramasamy Hamidon Basri Source Type: research
Redox Modulation of Meniere Disease by Coriolus Versicolor Treatment, a Nutritional Mushroom Approach with Neuroprotective Potential
CONCLUSIONS: Our study suggests MD as a model of cochlear neurodegenerative disease for the identification of potent inducers of the Nrf2-vitagene pathway, able to reduce the deleterious consequences associated with neurodegenerative damage, probably by indirectly acting on α-synuclein expression and on inflammatory processes NF- kB-mediated.PMID:38073105 | DOI:10.2174/1570159X22666231206153936 (Source: Current Neuropharmacology)
Source: Current Neuropharmacology - December 11, 2023 Category: Drugs & Pharmacology Authors: Rosanna Di Paola Rosalba Siracusa Roberta Fusco Marialaura Ontario Gaetano Cammilleri Licia Pantano Maria Scuto Mario Tomasello Sestina Span ò Angela Trovato Salinaro Ali S Abdelhameed Vincenzo Ferrantelli Antonio Arcidiacono Tilman Fritsch Gabriella Lup Source Type: research
Biphasic Hormetic-like Effect of Lebecetin, a C-type Lectin of Snake Venom, on Formalin-induced Inflammation in Mice
CONCLUSION: These findings implicate specific roles of integrins in inflammation and tonic pain, as well as in the related central nervous system sequelae.PMID:38073106 | DOI:10.2174/1570159X22999231207105743 (Source: Current Neuropharmacology)
Source: Current Neuropharmacology - December 11, 2023 Category: Drugs & Pharmacology Authors: Carmela Belardo Jed Jebali Serena Boccella Rosmara Infantino Antimo Fusco Michela Perrone Roozbe Bonsale Iolanda Manzo Monica Iannotta Damiana Scuteri Franca Ferraraccio Iacopo Panares Giovanna Ferrara Francesca Guida Livio Luongo Enza Palazzo Najet Srair Source Type: research
In Vitro Blood-Brain Barrier Models for Neuroinfectious Diseases: A Narrative Review
Curr Neuropharmacol. 2023 Dec 8. doi: 10.2174/1570159X22666231207114346. Online ahead of print.ABSTRACTThe blood-brain barrier (BBB) is a complex, dynamic, and adaptable barrier between the peripheral blood system and the central nervous system. While this barrier protects the brain and spinal cord from inflammation and infection, it prevents most drugs from reaching the brain tissue. With the expanding interest in the pathophysiology of BBB, the development of in vitro BBB models has dramatically evolved. However, due to the lack of a standard model, a range of experimental protocols, BBB-phenotype markers, and permeabili...
Source: Current Neuropharmacology - December 11, 2023 Category: Drugs & Pharmacology Authors: Ahmad Hussein Badawi Nur Afiqah Mohamad Johnson Stanslas Brian P Kirby Vasantha Kumari Neela Rajesh Ramasamy Hamidon Basri Source Type: research
Redox Modulation of Meniere Disease by Coriolus Versicolor Treatment, a Nutritional Mushroom Approach with Neuroprotective Potential
CONCLUSIONS: Our study suggests MD as a model of cochlear neurodegenerative disease for the identification of potent inducers of the Nrf2-vitagene pathway, able to reduce the deleterious consequences associated with neurodegenerative damage, probably by indirectly acting on α-synuclein expression and on inflammatory processes NF- kB-mediated.PMID:38073105 | DOI:10.2174/1570159X22666231206153936 (Source: Current Neuropharmacology)
Source: Current Neuropharmacology - December 11, 2023 Category: Drugs & Pharmacology Authors: Rosanna Di Paola Rosalba Siracusa Roberta Fusco Marialaura Ontario Gaetano Cammilleri Licia Pantano Maria Scuto Mario Tomasello Sestina Span ò Angela Trovato Salinaro Ali S Abdelhameed Vincenzo Ferrantelli Antonio Arcidiacono Tilman Fritsch Gabriella Lup Source Type: research
